J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
First published on May 28, 2008, doi:10.1177/0091270008320316

The Journal of Clinical Pharmacology 2008;48:919.

This Article
Right arrow Full Text (JCP OnlineFirst[PDF])
Right arrow All Versions of this Article:
0091270008320316v1
48/8/919    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Séchaud, R.
Right arrow Articles by Balez, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Séchaud, R.
Right arrow Articles by Balez, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
©© 2008 American College of Clinical Pharmacology, Inc.
The Journal of Clinical Pharmacology , 10.1177/0091270008320316

Article

Absolute Oral Bioavailability and Disposition of Deferasirox in Healthy Human Subjects

Romain Séchaud 1*, Anna Robeva 2, Rossella Belleli 1, and Sebastien Balez 3

1 Novartis Pharma AG
2 Novartis Pharmaceuticals
3 Novartis Pharmaceuticals SAS

* To whom correspondence should be addressed. E-mail: romain.sechaud{at}novartis.com.


  Abstract
Deferasirox is a novel iron chelator formulated as tablets for dispersion (suspension) for once-a-day oral administration. The current study evaluated the absolute bioavailability of a single 375-mg oral dose of deferasirox administered in the form of tablets compared with a 130-mg intravenous infusion of deferasirox. Since this was a first-in-man study using the deferasirox intravenous (IV) formulation, the safety and tolerability of the IV formulation was evaluated in a pilot phase with a lower dose (65 mg) in 3 subjects prior to the main phase. The main study phase consisted of 17 healthy male volunteers. Plasma concentrations of deferasirox were measured following each treatment, and pharmacokinetic parameters including absolute oral bioavailability were determined. Absolute oral bioavailability of the deferasirox tablets was 70% (90% confidence interval, 62%-80%). Deferasirox was characterized as having a low plasma clearance of 3.53 (± 0.87) L/h. A small volume of distribution of deferasirox at steady state (Vss) of 14.37 (±2.69 L) was determined, indicating a low tissue distribution.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
D. Chirnomas, A. L. Smith, J. Braunstein, Y. Finkelstein, L. Pereira, A. K. Bergmann, F. D. Grant, C. Paley, M. Shannon, and E. J. Neufeld
Deferasirox pharmacokinetics in patients with adequate versus inadequate response
Blood, November 5, 2009; 114(19): 4009 - 4013.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the American College of Clinical Pharmacology